Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
- 1 March 2002
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (4) , 615-618
Abstract
Objective To assess the occurrence of viral load greater than 50 copies/ml in patients on highly active antiretroviral therapy (HAART) having achieved less than 50 copies/ml and the chance of whether a viral load greater than 50 copies/ml would lead to a sustained and increasing viral load. Design A cohort of 553 patients on HAART with viral loads of less than 50 copies/ml were followed. Results Over a median of 56 weeks 35% of patients experienced a transient increase and 8% virological failure (two consecutive viral loads of > 400 copies/ml). Transient increases and virological failure were more common in those with greater drug experience, and those with initial raised viral load values of more than 400 copies/ml were more likely to have a sustained increase and become virological failures. Conclusion Transient increases in viral load are common, mainly in the 50–400 copies/ml range, and the majority of subsequent viral load estimations show a return to less than 50 copies/ml. A single raised viral load should lead to adherence support and intensified monitoring. Subsequent treatment decisions can then be based on evidence of true virological rebound and failure.Keywords
This publication has 11 references indexed in Scilit:
- Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Prevalence and Predictive Value of Intermittent Viremia With Combination HIV TherapyJAMA, 2001
- Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infectionAIDS, 2000
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Comparison of the Safety, Vaccine Virus Shedding, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold‐Adapted, Administered to Human Immunodeficiency Virus (HIV)–Infected and Non–HIV‐Infected AdultsThe Journal of Infectious Diseases, 2000
- Effect of Influenza Vaccination on Viral Replication and Immune Response in Persons Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapyNature Medicine, 2000
- The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurementsAIDS, 1999
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997